Abstract
Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular-targeted therapies has lead to reconsideration of the treatment strategy in differentiated thyroid cancer patients with distant metastases who are resistant to radioiodine therapy. In those with progressive disease, treatment with kinase inhibitors should be offered preferably in the context of a prospective trial.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Bone Neoplasms / diagnostic imaging
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / secondary
-
Carcinoma, Papillary / drug therapy
-
Carcinoma, Papillary / genetics
-
Clinical Trials as Topic
-
Disease Progression
-
Humans
-
Iodine Radioisotopes / therapeutic use
-
Lung Neoplasms / radiotherapy*
-
Lung Neoplasms / secondary*
-
Lymphatic Metastasis
-
MAP Kinase Signaling System / drug effects
-
Patient Selection
-
Randomized Controlled Trials as Topic
-
Research Design
-
Thyroid Neoplasms / drug therapy*
-
Thyroid Neoplasms / radiotherapy
-
Thyrotropin / antagonists & inhibitors
-
Thyroxine / therapeutic use
-
Tomography, X-Ray Computed
Substances
-
Iodine Radioisotopes
-
Thyrotropin
-
Thyroxine